Use the hyperlinks, where available to access additional clinical trial information.
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis
Other Non-Commercial Sponsor
National Health & Medical Research Council (NHMRC)
Patients enrolled in this trial will be randomly assigned to one of two treatment options. In group one, patients will receive the trial drug, Cyclophosphamide, for 5 days, followed by 90 days of cyclosporin. Patients in the other group will receive an existing medication regimen of cyclosporine and methotrexate, which is the current standard of care for Graft versus Host disease (GVHD) prevention.